Go to content

Tomorrow is Grown here

OUR STORY

Doing things differently since 1999.

The story of Medicago is rooted in a long track record of innovation and perseverance. Even our company name – the Latin word for alfalfa, which was the first plant we worked with – embodies our culture of adaptation. We're proud of our humble beginnings as much as we are of our current growth and global reach. We understand better than most that the path to success is not a straight line.

As a pioneer of plant-based transient expression and manufacturing, Medicago has always sought a more effective way to improve human health. With nearly 20 years of experience and wisdom behind us, we are ready to disrupt the traditional approach to vaccines and therapeutics.

Medicago has been privately held since 2013.

Here is a quick look at some of the key events and milestones that have helped shape the company as we exist today. 

2020

Medicago successfully produced a Virus-Like Particles (VLP) of the coronavirus in just 20 days and initiated Phase 1 in July.

Coronavirus VLP
2019

Medicago announces the results of a Phase 3 efficacy study of its seasonal flu vaccine candidate.

2018

Groundbreaking ceremony of the new Quebec City factory.

image
2017

Medicago announces the start of a Phase 3 efficacy study.

2015

Announcement of a major investment: Medicago will build a fully integrated manufacturing factory in Quebec City.

Mandate of the Public Health Agency of Canada (PHAC): Production of Ebola Virus Antibodies for the Sudan Strain.

2013

Mitsubishi Tanabe Pharmaceutical Corp. becomes majority shareholder of Medicago and the company (MDG) is de-listed from the Toronto Stock Exchange (TSX)

image
2012

Rapid fire test to produce more than 10M doses of H1N1 VLP vaccine in one month through a partnership with U.S. DARPA

Single dose of H5N1 VLP vaccine shows cross-protection against H5 and H2 strains

2011

Medicago builds a GMP manufacturing plant in Durham, North Carolina with the creation of Medicago USA

 

image
2009

Medicago announces production of the H1N1 Pandemic candidate vaccine 19 days after publication of the virus genetic sequence

2008

Philip Morris International joins Medicago's shareholding.

2006

Medicago's Initial Public Offering (IPO)

2005

Development of new transient expression technologies with Nicotiana benthamiana.

image
2003

Andy Sheldon joins as CEO, builds management team and changes the company business model to R&D pharmaceutical biotech focusing on vaccines & therapeutic proteins

Logo Medicago 2003

1999

Medicago incorporates after out-licensing the technology from Laval University and Agriculture Canada.

Logo Medicago 1999

1997

Partnership between Agriculture Canada and Laval University

Université Laval Logo

Today
1997
image

Takashi Nagao

President and Chief Executive Officer

Takashi Nagao joined Medicago as President and CEO in December 2020. He served as Medicago's Board of Directors since 2017 and as a Chairman since 2018, prior to his appointment, developing a deep understanding of the company's strategic objectives and core competencies.  Takashi is a proven leader in health innovation and the pharmaceutical space. He has led businesses through periods of accelerated growth and innovation, relying on his extensive knowledge of drug development and commercialization, business development and finance, and corporate management.

Previously, Takashi led the development of Mitsubishi Tanabe's presence in the US, holding leadership positions at MTPC Holdings Canada, Mitsubishi Tanabe Pharma Development America, MP Healthcare Venture Management, and Mitsubishi Tanabe Pharma America. In these roles, Takashi oversaw the early stage venture investment, translational research, clinical development, medical affairs, regulatory affairs, drug safety, supply management, quality assurance, marketing, managed market, legal and compliance, human resources and more.

image

Michael Morack

Chief Financial Officer

With over 30 years in various finance leadership roles in the healthcare sector, Michael brings strategic, analytical, and practical Finance acumen as Medicago's Chief Financial Officer. In this Executive Committee role reporting to Takashi Nagao, he is responsible for developing the Finance and IT strategy while driving these important functions at a critical time as Medicago transforms from a Research and Development focused organization to a successful Commercial company.

Michael gained his experience across the Finance and Information Technology landscape in a wide variety of dynamic healthcare environments ranging from Private Equity to IPO to Fortune 50. As a finance leader at Merck & Co., Michael held roles of increasing responsibility within the finance organization from Investor Relations, Financial Planning and Analysis to Controllership and served as the CFO of Sanofi Pasteur MSD, the vaccine joint venture created by Sanofi Pasteur and Merck for the commercialization of their products in Europe. Before joining Medicago, Michael served in Senior Vice President positions at Zelis Healthcare and ConvaTec Plc a medical device company, and while at ConvaTec he was instrumental in the transition from private equity ownership to a successful IPO listing on the London Stock Exchange.

Michael is a member of the Board of Directors for Giving Hope Network and is a both a Certified Public Accountant and Certified Management Accountant, holding a B.S. and an M.B.A. from Rider University.

image
At Medicago, we empower people to fulfill our purpose.
View profile

Lorrie Deyelle

Chief Human Resources Officer

Lorrie Deyelle has been transforming the way human resource groups develop, build and measure business value for over 30 years. As Chief Human Resources Officer at Medicago, Lorrie is the leader responsible for the identification, development, and implementation of global human resource strategies. She provides guidance to the Medicago Executive team, defining and transitioning internal client groups towards process improvement, increased outcome and customer service orientation, and cost-effectiveness. 

Prior, Lorrie held the positions of Head of Human Resources and Facilities for Kinapse Inc, CHRO for Carecentrix and Vice President of HR at PAREXEL International. Lorrie is certified nationally as GPHR and SCP through SHRM and CCP for World at Work. A magna cum laude graduate, she holds a BS in International Business from Franklin Piece University in Rindge, NH. Beyond to her corporate role, Lorrie is a Professor at Northeastern University where she has taught a variety of undergraduate classes and the SHRM certification prep class since 1999.  

image

Junya Namba

Executive Vice President Corporate Planning

Mr. Junya Namba, oversees the strategy and transformation office, the project management and the operational efficiency at Medicago since early 2021. Junya is a leader to develop strategy and key growth initiatives necessary to realise the strategic vision and build sustainable competitive advantages for the company.

Junya has been engaged in the pharmaceutical industry over 25 years in different business areas such as corporate planning & strategy, business development / license management, corporate management and sales & marketing.

He handled several leadership positions in 5 different countries in North America, Europe and Asia. Previously, he was a president of Mitsubishi Tanabe Pharma GmbH in Germany and led development of the European business.

He provides the company with guidance to realise a sustainable growth, offering clear goals and value-added strategic insights under the challenging and diversified market in the world.

image
Strong collaboration leads to the best kind of science, and that includes working with talented researchers and specialists, not only within Medicago, but across industry, governments and academia.
View profile

Marc-André D'Aoust

Executive Vice President, Innovation Development & Medical Affairs

Dr. Marc-André D'Aoust is a pioneer of Medicago and joined the company at the beginning in 1999. Passionate about science and innovation, he has, over the years, led the development of the plant-based Proficia® technology, the virus-like particle (VLP) vaccine technology and the VLPExpress®  high-throughput discovery platform of the company.

As Executive Vice President Research, Innovation and Medical Affairs, he advances Medicago's technological vision and is responsible for the discovery, the development and the protection of the technological assets of the company. He is co-inventor on more than 700 patents and patent applications related to the platform or the products of the company. He studied plant biochemistry and molecular biology at Laval University where he received his Ph.D. in 2000.

image
I am delighted to join Medicago at a critical moment of its evolution, I am confident to lead the teams through this transformation.

Scot DeAthos

Executive Vice President of Operations

Scot is a leader, passionate about manufacturing and people. He aims at mentoring, coaching and developing his team and beyond. He always keeps in mind that people are the keys to succeed when you transform and challenge the status quo.

At Medicago, Scot is overseeing Global Manufacturing Operations and Supply Chain.

He has a broad experience in biopharmaceuticals with a focus in driving organizational performance improvement. He assumed several leadership positions in large and small molecule companies such as Baxter Bioscience, MedImmune, AstraZeneca, and prior joining Medicago at Braeburn.

He succeeded in transforming manufacturing organizations by building a Lean manufacturing culture and sytems, leadership capability and engaging teams.

Scot joined Medicago early 2021, bringing his strategic vision and operational knowledge to the team.

He earned an MS degree in Chemical Engineering from the Michigan State University.

image

Sarah Marquis

Vice President Legal Affairs

image
I am looking forward to working with different countries to help the fight against infectious diseases by bringing our vaccines to market.
View profile

Nicolas Petit

Vice President, Commercial Operations

Nicolas is responsible for Sales & Marketing, Business Development, External Communications and External Affairs.

He joined Medicago in 2017 as Senior Director of Marketing.

Prior to joining Medicago, Nicolas worked for Sanofi for 10 years; based in 5 different countries in Europe, Asia and Eurasia; and gained experience in a large span of commercial functions including sales & marketing, launch readiness, business development and operational excellence.

Nicolas earned a Master of international management and a degree of Engineer in agronomy.
 

OUR LEADERSHIP TEAM

image

Michael Alltoft

Vice President, Engineering

image

Judith Atkins

Vice President, Regulatory Affairs

image

Pam Caplin

Vice President, Human Resources

image

Patrick Lim

Vice President, Finance

image

Kathryn Simon

Vice President, Quality Control

image

Sylvie St-Martin

Vice President, Quality Assurance

image

Jim Zemonek

Vice President, Information Technology

image

Michael Alltoft

Vice President, Engineering

image

Judith Atkins

Vice President, Regulatory Affairs

image

Pam Caplin

Vice President, Human Resources

image

Patrick Lim

Vice President, Finance

image

Asif Mahmood

Chief Safety Officer and Vice President Global Safety & Pharmacovigilance

Asif Mahmood, M.D., M.P.H., M.B.A., has served as our Chief Safety Officer/Vice President Global Safety & Pharmacovigilance since July 2019.  Prior to joining Medicago, Asif Mahmood held several roles of increasing responsibility from Director to Associate Vice President at Pfizer, Sanofi, Genzyme, Sanofi Pasteur and Apotex in the US and Canada from 2004 to 2019. 

He has experience of working on many diverse therapeutic areas including Vaccines, hepatology, oncology, infectious diseases, rare diseases, biosimilars, drug delivery devices, generics, and OTC.

Earlier in his career, he served as the Deputy Director General, Federal Ministry of Health in Islamabad, Pakistan, and as Medical Director and Joint Executive Director for Pakistan Institute of Medical Sciences and Children's hospital Islamabad. He has also served on many public health and immunization projects of WHO, UNICEF and Japan International Corporation Agency. He received his M.D., from King Edwards Medical University in Pakistan, in addition to completing M.P.H and M.B.A. 

image

Kathryn Simon

Vice President, Quality Control

image

Sylvie St-Martin

Vice President, Quality Assurance

image
One of the best things about working at Medicago is the opportunity to work with world-class scientists in both the industrial and academic sectors to develop the company's game-changing technologies. At Medicago, we recognize the contribution every person in our business can make to the introduction of innovative products that can address some of the world's most pressing health challenges.

Brian J. Ward

Medical Officer

Dr. Brian Ward is passionate about science and innovation. He has active research interests in RNA viruses, vaccine development and international health supported by Canadian and international funding agencies as well as private foundations and industry.

He is a Professor of Medicine and Microbiology at McGill University and serves on several national and international advisory committees in the areas of vaccine use, vaccine safety and international health.

 

image

Jim Zemonek

Vice President, Information Technology

Where we work

North American roots with global ambitions.

Quebec City

Quebec  |  Canada

Medicago's history and head office are based in Quebec City, Canada where the research, product development, process development, and management functions are located. We have a 2,300m2 cGMP pilot production facility and a 1,300m2 greenhouse that meets strict confinement standards.

Medicago is currently building a new multi-million dollar complex in Quebec that will support our growing workforce and commercial production. The new facility will increase our production and research capacity for future projects such as pandemic flu, new vaccines, monoclonal antibodies, and other protein-based therapeutics.

Learn more about life at
Medicago's headquarters

Raleigh-Durham

North Carolina  |  USA

Medicago USA, a wholly-owned subsidiary, is located in the Research Triangle Park (RTP) in North Carolina. Medicago USA's operations started in 2010 through a partnership with the U.S. Defense Advanced Research Projects Agency (DARPA). Our complex in RTP includes a 10,000m2 cGMP facility with a fully automated greenhouse and a state-of-the-art extraction and purification unit.

Learn more about life
at Medicago USA

Our Network

Collaboration has long been a driver of our success. 

When it comes to addressing global health challenges, it's impossible to go at it alone. Medicago's technological and clinical accomplishments have been possible in large part thanks to the long-time, meaningful partnerships we've established with some of the leading educational institutions, researchers, and government agencies.

Finances Québec
Économie science et innovation
Cqdm
Développement économique Canada pour les régions du Québec
Santé Canada
Public Health Agency of Canada
Ville de Québec
Québec international
Defence RID
Genome Québec
CEA
Darpa
Path
Immunovaccine
Université Laval
nfid
nrc-cnrc

Interested in a potential partnership with Medicago?